Travere Therapeutics, Inc. Common Stock (TVTX) Stock Price

TVTXStock

$49.60+80.30%52W

Market Cap$4.61B

P/E—

PEG Ratio—

Div yield—

Beta1.09

TVTX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)7.83%

Price vs S&P 500 (4W)-19.77%

VGM Score56.99

P/CF (Annual)123.74x

Book Value / Share (Quarterly)$0.26

P/TBV (Annual)1995.76x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)32.28%

Cash Flow / Share (Quarterly)$0.16

Price vs S&P 500 (YTD)17.88%

Gross Margin (TTM)98.60%

Net Profit Margin (TTM)-7.35%

EPS (TTM)$-0.50

10-Day Avg Trading Volume2.10M

EPS Excl Extra (TTM)$-0.50

Revenue Growth (5Y)19.87%

EPS (Annual)$-0.29

ROI (Annual)-5.99%

Gross Margin (Annual)97.89%

Net Profit Margin (5Y Avg)-86.07%

Cash / Share (Quarterly)$5.19

Revenue Growth QoQ (YoY)48.17%

ROA (Last FY)-4.22%

Revenue Growth TTM (YoY)77.12%

EBITD / Share (TTM)$0.23

ROE (5Y Avg)-266.16%

Operating Margin (TTM)-6.84%

Cash Flow / Share (Annual)$-0.22

P/B Ratio190.66x

P/B Ratio (Quarterly)215.44x

Net Income / Employee (Annual)$-51,400

EV / Revenue (TTM)8.73x

Net Interest Coverage (TTM)-54.64x

ROA (TTM)-6.96%

EV / EBITDA (TTM)242.19x

EPS Incl Extra (Annual)$-0.29

Current Ratio (Annual)2.74x

Quick Ratio (Quarterly)3.75x

3-Month Avg Trading Volume1.75M

52-Week Price Return80.30%

Revenue / Employee (TTM)$1,189,800

Tangible BV / Share (Quarterly)$0.02

P/S Ratio (Annual)9.53x

Asset Turnover (Annual)0.81x

52-Week High$68.73

Operating Margin (5Y Avg)-123.87%

EPS Excl Extra (Annual)$-0.29

CapEx CAGR (5Y)18.81%

Tangible BV CAGR (5Y)-58.03%

26-Week Price Return17.73%

Quick Ratio (Annual)2.52x

13-Week Price Return-12.54%

Total Debt / Equity (Annual)2.71x

Current Ratio (Quarterly)4.05x

Enterprise Value$5.16B

Revenue / Share Growth (5Y)5.67%

Asset Turnover (TTM)0.95x

Book Value / Share Growth (5Y)-20.77%

Revenue / Employee (Annual)$987,400

Inventory Turnover (Annual)1.71x

Pretax Margin (Annual)-10.04%

Cash / Share (Annual)$3.55

3-Month Return Std Dev42.03%

Gross Margin (5Y Avg)96.02%

Net Income / Employee (TTM)$-87,500

ROE (Last FY)-22.25%

Net Interest Coverage (Annual)0.10x

EPS Basic Excl Extra (Annual)$-0.29

P/FCF (TTM)59.32x

Receivables Turnover (TTM)9.91x

EV / Free Cash Flow (TTM)335.11x

Total Debt / Equity (Quarterly)24.58x

EPS Incl Extra (TTM)$-0.50

Receivables Turnover (Annual)9.15x

ROI (TTM)-9.40%

P/S Ratio (TTM)7.91x

Pretax Margin (5Y Avg)-123.33%

Revenue / Share (Annual)$5.50

Tangible BV / Share (Annual)$0.02

Forward P/E32.37x

Price vs S&P 500 (52W)64.77%

Year-to-Date Return29.81%

5-Day Price Return-4.65%

EPS Normalized (Annual)$-0.29

ROA (5Y Avg)-27.41%

Net Profit Margin (Annual)-5.21%

Month-to-Date Return-15.76%

Cash Flow / Share (TTM)$-4.45

EBITD / Share (Annual)$-0.04

Operating Margin (Annual)-12.80%

LT Debt / Equity (Annual)2.71x

P/CF (TTM)50.44x

ROI (5Y Avg)-39.86%

LT Debt / Equity (Quarterly)24.58x

EPS Basic Excl Extra (TTM)$-0.50

P/TBV (Quarterly)1995.76x

P/B Ratio (Annual)29.77x

Inventory Turnover (TTM)1.39x

Pretax Margin (TTM)-11.34%

Book Value / Share (Annual)$1.26

Price vs S&P 500 (13W)-15.22%

Beta1.09x

Revenue / Share (TTM)$6.33

ROE (TTM)-55.79%

52-Week Low$22.59

vGradeF

gGradeB

mGradeB

vgmGradeC

TVTX Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 4, 2026	$0.32	-$0.10	-131.02%(-$0.42)
Q1 2026	May 4, 2026	-$0.06	$0.05	+187.00%(+$0.11)
Q4 2025	Feb 19, 2026	$0.37	$0.37	-0.77%(-$0.00)
Q3 2025	Oct 30, 2025	-$0.09	$0.59	+794.12%(+$0.67)
Q2 2025	Aug 6, 2025	$0.04	$0.13	+225.00%(+$0.09)

TVTX Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.29

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
TVTXTravere Therapeutics, Inc. Common Stock	F	B	B	7.9x	77.1%	98.6%	—	$49.60
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Travere Therapeutics, Inc. Common Stock

Travere Therapeutics is a biopharmaceutical company developing therapies for rare kidney, liver, and metabolic diseases. Its lead candidate, sparsentan, is in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN), both rare kidney disorders that can progress to end-stage kidney disease. The company is also advancing pegtibatinase, an investigational enzyme replacement therapy for HCU, a genetic metabolic disorder.

TVTX Next Earnings Report

Report dateOct 29, 2026

QuarterQ3 2026

Report timeAMC

EPS estimate$0.49

Revenue estimate$195.68M

Also reporting on Oct 29, 2026

Scheduled date with consensus estimates — both can change before the company reports.

Earnings calendar for October 2026

Companies in Related Industries

SRRKScholar Rock Holding Corporation Common StockBiological Products
CRSPCRISPR Therapeutics AGBiological Products
RGCRegencell Bioscience Holdings Limited Ordinary SharesPharmaceutical Preparations
CSWCSW Industrials, Inc.Adhesives & Sealants
PRMPerimeter Solutions, Inc.Chemicals
DFTXDefinium Therapeutics, Inc. Common SharesPharmaceutical Preparations
CBTCabot CorporationIndustrial Chemicals
ADPTAdaptive Biotechnologies Corporation Common StockBiological Products

Same SIC sector, outside this company's own industry.

Analyst Sentiment

4.3

Strong Buy

Consensus rating

52-Week Range

Low$22.59

High$68.73